A zebrafish genetic model of Ewing sarcoma, a pediatric bone cancer, showed how molecules in the normal tissue can support tumor cells, and identified a therapeutic compound that slows tumor growth.

STAG1 has been identified as a hardwired genetic dependency of cancer cells harbouring mutations in the cohesin subunit and emerging major tumor suppressor STAG2 holds the promise for the development of selective therapeutics.

BRD9 provides the first actionable therapeutic target in synovial sarcoma tumours that is both biochemically and functionally linked to the SS18-SSX fusion protein which drives disease development.

Editors' Summary: This Replication Study has reproduced some parts of the original paper but other parts could not be interpreted.

Zebrafish are an optimal model organism to study rare TP53 mutations whose functions are not readily understood.

The basic helix-loop-helix transcription factor, HES3, acts downstream of the PAX3-FOXO1 fusion oncogene to impair muscle differentiation and promote tumorigenesis in rhabdomyosarcoma, a childhood muscle cancer.

The loss of p53 in bone cells activates critical signaling pathways; these are also essential in bone cancer.

The current understanding of phase separation is summarized and its emerging roles in cancer are discussed in detail.